Can-Fite BioPharma (CANF) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.76, -4.86% vs the prior close of $1.85.
- Volume 26.98K shares, 0.1x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CANF slides 4.9% to $1.76, a 52-week low, 4 down days in a row. Closed at $1.76, -4.86% vs the prior close of $1.85. Day range $1.75–$1.92, opened at $1.92.
CANF daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CANF slides 4.9% to $1.76, a 52-week low, 4 down days in a row
- Closed at $1.76, -4.86% vs the prior close of $1.85. Day range $1.75–$1.92, opened at $1.92.
- Volume was 26.98K shares, 0.1x its 50-day average of 457.41K — lighter than usual.
- Price is -32.0% vs its 50-day average ($2.59) and -47.2% vs its 200-day average ($3.33).
- 52-week range $1.75–$12.40; today's close sits at 0% of that range, 85.8% below the 52-week high.
- That makes 4 straight losses.
Oct 15, 2026 — CANF slides 4.1% to $1.85, a 52-week low, 3 down days in a row
- Closed at $1.85, -4.15% vs the prior close of $1.93. Day range $1.85–$1.93, opened at $1.93.
- Volume was 26.60K shares, 0.1x its 50-day average of 457.61K — lighter than usual.
- Price is -29.5% vs its 50-day average ($2.63) and -44.7% vs its 200-day average ($3.34).
- 52-week range $1.85–$12.40; today's close sits at 0% of that range, 85.1% below the 52-week high.
- That makes 3 straight losses.
Oct 14, 2026 — CANF dips 1.0% to $1.93
- Closed at $1.93, -1.03% vs the prior close of $1.95. Day range $1.90–$1.95, opened at $1.95.
- Volume was 15.50K shares, 0.0x its 50-day average of 457.95K — lighter than usual.
- Price is -27.2% vs its 50-day average ($2.65) and -42.4% vs its 200-day average ($3.35).
- 52-week range $1.90–$12.40; today's close sits at 0% of that range, 84.4% below the 52-week high.
Oct 13, 2026 — CANF ends flat (+0.0%) to $1.95
- Closed at $1.95, +0.00% vs the prior close of $1.95. Day range $1.91–$2.00, opened at $1.97.
- Volume was 19.60K shares, 0.0x its 50-day average of 458.22K — lighter than usual.
- Price is -27.2% vs its 50-day average ($2.68) and -42.0% vs its 200-day average ($3.36).
- 52-week range $1.90–$12.40; today's close sits at 0% of that range, 84.3% below the 52-week high.
Oct 12, 2026 — CANF rises 2.6% to $1.95
- Closed at $1.95, +2.63% vs the prior close of $1.90. Day range $1.91–$2.02, opened at $1.91.
- Volume was 24.30K shares, 0.1x its 50-day average of 458.04K — lighter than usual.
- Price is -27.8% vs its 50-day average ($2.70) and -42.2% vs its 200-day average ($3.37).
- 52-week range $1.90–$12.40; today's close sits at 0% of that range, 84.3% below the 52-week high.
Oct 9, 2026 — CANF slides 5.0% to $1.90, a 52-week low, 6 down days in a row
- Closed at $1.90, -5.00% vs the prior close of $2.00. Day range $1.90–$2.01, opened at $1.98.
- Volume was 34.00K shares, 0.1x its 50-day average of 458.33K — lighter than usual.
- Price is -30.3% vs its 50-day average ($2.73) and -43.9% vs its 200-day average ($3.39).
- 52-week range $1.90–$12.40; today's close sits at 0% of that range, 84.7% below the 52-week high.
- That makes 6 straight losses.
Oct 8, 2026 — CANF slides 4.8% to $2.00, a 52-week low, 5 down days in a row
- Closed at $2.00, -4.76% vs the prior close of $2.10. Day range $1.96–$2.12, opened at $2.10.
- Volume was 68.30K shares, 0.1x its 50-day average of 457.46K — lighter than usual.
- Price is -27.4% vs its 50-day average ($2.75) and -41.2% vs its 200-day average ($3.40).
- 52-week range $1.96–$12.40; today's close sits at 0% of that range, 83.9% below the 52-week high.
- That makes 5 straight losses.
Oct 7, 2026 — CANF dips 1.9% to $2.10, a 52-week low, 4 down days in a row
- Closed at $2.10, -1.87% vs the prior close of $2.14. Day range $2.10–$2.14, opened at $2.14.
- Volume was 43.80K shares, 0.1x its 50-day average of 457.01K — lighter than usual.
- Price is -24.4% vs its 50-day average ($2.78) and -38.5% vs its 200-day average ($3.41).
- 52-week range $2.10–$12.60; today's close sits at 0% of that range, 83.3% below the 52-week high.
- That makes 4 straight losses.
Oct 6, 2026 — CANF ends flat (+0.0%) to $2.14, 3 down days in a row
- Closed at $2.14, +0.00% vs the prior close of $2.14. Day range $2.11–$2.14, opened at $2.14.
- Volume was 23.80K shares, 0.1x its 50-day average of 456.94K — lighter than usual.
- Price is -23.5% vs its 50-day average ($2.80) and -37.6% vs its 200-day average ($3.43).
- 52-week range $2.11–$12.80; today's close sits at 0% of that range, 83.3% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — CANF dips 1.8% to $2.14, a 52-week low
- Closed at $2.14, -1.83% vs the prior close of $2.18. Day range $2.12–$2.15, opened at $2.15.
- Volume was 27.90K shares, 0.1x its 50-day average of 457.12K — lighter than usual.
- Price is -24.1% vs its 50-day average ($2.82) and -37.9% vs its 200-day average ($3.45).
- 52-week range $2.12–$12.80; today's close sits at 0% of that range, 83.3% below the 52-week high.
Oct 2, 2026 — CANF dips 1.4% to $2.18
- Closed at $2.18, -1.36% vs the prior close of $2.21. Day range $2.18–$2.22, opened at $2.20.
- Volume was 27.30K shares, 0.1x its 50-day average of 457.01K — lighter than usual.
- Price is -23.2% vs its 50-day average ($2.84) and -37.1% vs its 200-day average ($3.46).
- 52-week range $2.14–$12.80; today's close sits at 0% of that range, 83.0% below the 52-week high.
CANF latest news & SEC filings
Every SEC filing by or about CANF in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 25, 2026 · Form F-3 — F-3 filing
F-3 filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 11, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 11, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 9, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 8, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 3, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 2, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 2, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade CANF
- How much it moves: over the last 20 sessions the average daily move was 1.99% (largest 5.0%).
- Liquidity: about 33.77K shares (≈$59.44K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.76 vs a range of $1.75–$12.40 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:20 on Jan 5, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Sep 9, 2026; 6-K Sep 8, 2026; 6-K Sep 3, 2026.
- Listing: NYSE · industry: Pharmaceutical Preparations.
CANF market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.92 | 1.92 | 1.75 | 1.76 | 26.98K |
| Oct 15, 2026 | 1.93 | 1.93 | 1.85 | 1.85 | 26.60K |
| Oct 14, 2026 | 1.95 | 1.95 | 1.90 | 1.93 | 15.50K |
| Oct 13, 2026 | 1.97 | 2.00 | 1.91 | 1.95 | 19.60K |
| Oct 12, 2026 | 1.91 | 2.02 | 1.91 | 1.95 | 24.30K |
| Oct 9, 2026 | 1.98 | 2.01 | 1.90 | 1.90 | 34.00K |
| Oct 8, 2026 | 2.10 | 2.12 | 1.96 | 2.00 | 68.30K |
| Oct 7, 2026 | 2.14 | 2.14 | 2.10 | 2.10 | 43.80K |
| Oct 6, 2026 | 2.14 | 2.14 | 2.11 | 2.14 | 23.80K |
| Oct 5, 2026 | 2.15 | 2.15 | 2.12 | 2.14 | 27.90K |
| Oct 2, 2026 | 2.20 | 2.22 | 2.18 | 2.18 | 27.30K |
| Oct 1, 2026 | 2.20 | 2.25 | 2.19 | 2.21 | 34.60K |
| Sep 30, 2026 | 2.21 | 2.27 | 2.19 | 2.20 | 61.50K |
| Sep 29, 2026 | 2.23 | 2.23 | 2.14 | 2.18 | 34.80K |
| Sep 28, 2026 | 2.14 | 2.23 | 2.14 | 2.23 | 36.50K |
| Sep 25, 2026 | 2.22 | 2.22 | 2.15 | 2.16 | 28.70K |
| Sep 24, 2026 | 2.16 | 2.22 | 2.15 | 2.17 | 39.40K |
| Sep 23, 2026 | 2.21 | 2.22 | 2.15 | 2.16 | 43.10K |
| Sep 22, 2026 | 2.22 | 2.26 | 2.20 | 2.23 | 33.80K |
| Sep 21, 2026 | 2.28 | 2.28 | 2.22 | 2.22 | 25.00K |
About Can-Fite BioPharma
Can-Fite BioPharma (CANF) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in RAMAT GAN, Israel. State of incorporation: Israel. Fiscal year ends December 31. SEC CIK 1536196.
CANF board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Yoseph Bornstein | Director | Mar 18, 2026 |
| Pnina Fishman | Chief Scientific Officer | Jun 8, 2026 |
| Guy Regev | Director | Apr 6, 2026 |
| Abraham Sartani | Director | Mar 18, 2026 |
| Ilan Tamir | Director | Apr 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Motti Farbstein | CEO, CFO and COO | Jun 8, 2026 |
| Pnina Fishman | Chief Scientific Officer | Jun 8, 2026 |
| Sari Fishman | VP Business Development | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
CANF financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
CANF earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CANF
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.